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Abstract
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various 
cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly Inherited 
Alzheimer Network and ultrasensitive immunoas-say technology to demonstrate that NfL levels in 
the cerebrospinal fluid (n = 187) and serum (n = 405) are correlated with one another and are 
elevated at the presymptomatic stages of familial Alzheimer’s disease. Longitudinal, within-
person analysis of serum NfL dynamics (n = 196) confirmed this elevation and further revealed 
that the rate of change of serum NfL could discriminate mutation carriers from non-mutation 
carriers almost a decade earlier than cross-sectional absolute NfL levels (that is, 16.2 versus 6.8 
years before the estimated symptom onset). Serum NfL rate of change peaked in participants 
converting from the presymptomatic to the symptomatic stage and was associated with cortical 
thinning assessed by magnetic resonance imaging, but less so with amyloid-β deposition or 
glucose metabolism (assessed by positron emission tomography). Serum NfL was predictive for 
both the rate of cortical thinning and cognitive changes assessed by the Mini–Mental State 
Examination and Logical Memory test. Thus, NfL dynamics in serum predict disease progression 
and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer’s disease, 
which supports its potential utility as a clinically useful biomarker.
Reprints and permissions information is available at www.nature.com/reprints.
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In most neurodegenerative diseases, brain changes manifest many years before clinical 
symptoms become apparent. In Alzheimer’s disease, presymptomatic changes in the brain 
include cortical thinning and neuropathological depositions containing amyloid-β and tau. 
These pathological changes can be assessed by magnetic resonance imaging (MRI), 
positron-emission tomography (PET), and measurement of amyloid-β and tau protein levels 
in the cerebrospinal fluid (CSF)1–4. However, CSF collection is invasive and imaging 
modalities are expensive; therefore, they are not well suited to routine clinical practice. 
Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, 
although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain 
(NfL) in the blood have been reported5–10.
NfL is a component of the axonal cytoskeleton and is primarily expressed in large-caliber 
myelinated axons11,12. Changes of NfL in bodily fluids have been linked to brain damage 
and brain atrophy in mouse models and multiple neurological disorders including 
proteopathic neurodegenerative diseases11,13–16. Advancements in NfL measurements have 
revealed tight correlations between NfL in the CSF and blood and have sparked interest in 
an NfL blood-based biomarker that monitors neurodegeneration and disease progression. 
However, longitudinal analyses are largely missing and the importance of NfL as a 
molecular biomarker for the presymptomatic phase of neurodegenerative diseases remains 
unclear6,9,17.
We made use of the Dominantly Inherited Alzheimer Network (DIAN)18 data and 
biospecimens to study NfL changes in the CSF and blood of presymptomatic and 
symptomatic Alzheimer’s disease. DIAN participants are members of families carrying 
highly penetrant autosomal-dominant mutations in the genes encoding the amyloid beta 
precursor protein (APP) or presenilin 1 (PSEN1) or 2 (PSEN2)19. Family members who do 
not carry the mutations serve as controls. Since the age of symptom onset tends to be 
consistent for a given mutation, it is possible to calculate for participants an estimated years 
to symptom onset (EYO) from the known onset of individuals with the same mutation20.
We used the single-molecule array immunoassay technology to measure NfL in the CSF and 
blood serum of DIAN participants at their baseline (initial) visit (mutation carriers, n = 243; 
non-carriers, n = 162) (see Supplementary Table 1 for participant characteristics). 
Multivariate linear mixed effects models (LMEMs) served to assess the earliest point in the 
disease when NfL starts to increase in mutation carriers in relation to non-carriers (Fig. 
1a,b). Results revealed that NfL in the CSF was significantly increased between mutation 
carriers and non-carriers at −6.8 EYO (Fig. 1a, Extended Data Fig. 1a). Almost identically, 
serum NfL was also increased at −6.8 EYO (Fig. 1b; Extended Data Fig. 1b). Consistent 
with our earlier work13 CSF and serum NfL levels were tightly associated (Fig. 1c,d). No 
differences in CSF or serum NfL levels between the three familial Alzheimer’s disease 
mutations were found (Extended Data Fig. 2).
Given the strong association between serum and CSF NfL, and the obvious advantage of a 
non-invasive disease blood biomarker21, we chose to focus on serum NfL for subsequent 
longitudinal analyses. From the 405 participants with baseline serum, 196 returned for at 
least 1 and maximally 5 follow-up visits, with a mean number of 2.5 visits and a median 
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observation time of 3 years from the baseline visit (see Supplementary Table 2 for the 
longitudinal characteristics of participants).
Overall, the longitudinal analysis of serum NfL confirmed the cross-sectional findings (Fig. 
2a). Using LMEMs we calculated the slope of NfL change per year for each participant. As 
with cross-sectional values, the NfL rates of change were significantly elevated in mutation 
carriers relative to non-carriers. Strikingly, however, the first EYO point where this increase 
became significant was at − 16.2 years (Fig. 2b; see also Extended Data Fig. 3), which is 
almost a decade earlier than the cross-sectional baseline estimates (−6.8 EYO, see earlier). 
Consistent with this earlier separation of mutation carriers and non-carriers using 
longitudinal measurements, the rate of change could distinguish presymptomatic mutation 
carriers from non-carriers more accurately compared to base-line serum NfL using receiver 
operating characteristics analysis (Extended Data Fig. 4).
Next, we subdivided mutation carriers into three groups: presymptomatic mutation carriers 
(individuals who scored 0 on the Clinical Dementia Rating (CDR) scale across all visits); 
converters (CDR = 0 at baseline and CDR > 0 at subsequent visits); and symptomatic 
mutation carriers (CDR > 0 across all visits). Then we compared the rate of change in serum 
NfL across these groups. Analyses revealed that the rate of change in serum NfL peaked in 
the converter group with no further increase in the symptomatic carriers (Fig. 2c). 
Interestingly, flattening or even U-shaped curves have also been observed in longitudinal 
studies for CSF biomarkers in dominant and sporadic AD22,23.
No differences in NfL rate of change were found between mutations in APP, PSEN1, and 
PSEN2 (Extended Data Fig. 5a). To analyze whether the NfL rate of change was associated 
with the aggressiveness of individual mutations or EYO, we analyzed how far away the NfL 
rate of change of each mutation carrier was from the median value from the model estimates 
at that individual’s EYO (Extended Data Fig. 5b). Although we did not find any significant 
differences, it is possible that differences become apparent when the number of individuals 
and longitudinal data points increase.
To study if brain changes are coupled with changes in serum NfL, regression analysis 
between NfL rates of change and rates of change in brain imaging modalities were 
performed. We focused on the precuneus since previous analyses have shown this area to be 
most sensitive to Alzheimer’s disease progression2,24. NfL rates of change in serum and 
rates of precuneus cortical thinning were significantly associated in symptomatic mutation 
carriers with a trend toward significance in presymptomatic mutation carriers (Fig. 3a). The 
rate of change in serum NfL and the rate of change in precuneus glucose metabolism (18F-
fluorodeoxyglucose (18F-FDG) PET) were significantly associated in symptomatic mutation 
carriers but not in presymptomatic mutation carriers (Fig. 3b). Although there was a positive 
relationship between NfL rate of change and the rate of change in precuneus amyloid-β 
deposition (amyloid-β-PET), the association did not reach significance (Fig. 3c). These 
results indicate that NfL changes in the blood most closely reflect cortical thinning and 
support the view that serum NfL is primarily a marker of neurodegeneration.
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To examine the utility of serum NfL for predicting subsequent neurodegeneration and 
clinical symptoms, we performed a (retrospective) pseudo-predictive analysis to ask whether 
baseline serum NfL levels were predictive of subsequent cortical thinning (Fig. 4a). In 
addition, we assessed the predictability of baseline serum NfL for detecting change in two 
cognitive parameters, namely the Mini–Mental State Examination (MMSE) and the Logical 
Memory test (Fig. 4b,c). Indeed, baseline NfL was highly predictive of future annualized 
cortical thinning, for both presymptomatic and symptomatic mutation carriers, at subsequent 
visits (Fig. 4a) and was also predicative for a decrease in MMSE and Logical Memory 
scores (Fig. 4b,c).
To examine whether serum NfL is also predictive in a truly prospective design, the first 39 
mutation carriers returning for follow-up visits after the last serum collection were included 
in the analysis. (The median time between last serum collection and subsequent visit was 2.1 
years.) This prospective analysis allowed us to use the serum NfL rate of change for the 
prediction of further cortical thinning and cognitive changes (from the last visit with serum 
collection to the follow-up visit). Despite the small sample size, significant (predictive) 
associations were found between serum NfL rate of change and cortical thinning as well as 
MMSE and Logical Memory test (Fig. 4d–f).
Cross-sectional and longitudinal data analyses of DIAN and other large Alzheimer’s disease 
cohorts have demonstrated that the pathological processes in Alzheimer’s disease begin 
more than two decades before the onset of clinical symptoms. The accumulation of amyloid-
β in the brain (estimated 15–20 years before clinical onset) is followed by declines in 
cortical metabolism (estimated 10–15 years before clinical onset) and brain atrophy (5–10 
years before clinical onset)1,2,22,25. Thus, it is generally agreed that therapeutic interventions 
should start as early as possible making disease bio-markers of the presymptomatic phase of 
utmost importance4,26. The present results suggest that NfL levels in the blood may serve as 
such a biomarker to monitor neurodegeneration and disease progression already in 
presymptomatic Alzheimer’s disease.
The strong association between NfL levels in the CSF and blood indicates that NfL changes 
in the blood reflect changes in the brain, a finding also reported for other neurodegenerative 
diseases including sporadic Alzheimer’s disease6,13,27,28. In the present study serum was 
analyzed but similar levels and tight correlations have also been reported for NfL in the 
plasma13,27. The antigen detected with the (ultrasensitive) immunoassay used in this study is 
presumably a short and stable fragment (~10 kD) of the core domain of NfL15,29. Such a 
stable fragment appears well suited as a blood biomarker for monitoring a slow 
neurodegenerative process in the brain.
Using serial NfL measurements we found that the NfL annual rate of change can distinguish 
non-carriers and mutation carriers as early as 16 years before the estimated symptom onset. 
This is almost a decade earlier than when using absolute NfL levels measured at a single 
time point. Consistently, previous studies reported only non-significant or barely significant 
increases in absolute NfL in the blood in presymptomatic or even mildly cognitive impaired 
Alzheimer’s disease patients6,9,13. In symptomatic Alzheimer’s disease, our results suggest 
that the NfL rate of change reaches a plateau, whereas absolute NfL levels continue to 
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increase. Increased absolute NfL levels in the blood in the symptomatic disease phase is 
consistent with similar observations in progressive supranuclear palsy28, Huntington’s 
disease30, and multiple sclerosis14.
The very early changes of NfL in the blood may appear surprising in light of the reported 
overall brain atrophy only 5–10 years before symptom onset. However, atrophy of individual 
cortical regions occurs earlier1,2,22,25. In fact, precuneus thinning was also detected around 
16 years before symptom onset2, suggesting that NfL changes are sensitive enough to pick 
up such early regional brain atrophy. The association between NfL and cortical thinning, 
rather than amyloid-β deposition, is in line with cerebral amyloid-β aggregation being a 
trigger of subsequent neurodegeneration that, however, become independent of each other at 
later disease stages31. The relationship of NfL to tau in bodily fluids needs further work. In 
the DIAN cohort, the increase of tau in the CSF (absolute levels, cross-sectional) occurs as 
early as 15 years before the estimated age of symptom onset32, which is much earlier than 
the increase of base-line NfL in the CSF.
While an increase of NfL levels is not specific for Alzheimer’s disease, the present findings 
are relevant for understanding Alzheimer’s disease progression and highlight their utility as 
a marker in clinical trials. In presymptomatic Alzheimer’s disease, the greater the NfL rate 
of change, the closer an individual is to converting to symptomatic Alzheimer’s disease, a 
finding also reported for cortical atrophy2,33. This suggests that longitudinal measures of 
NfL in the serum are a reliable, relatively cheap, and fast readout of neurodegeneration in 
the brain with comparable diagnostic value to neuroimaging but without the regional 
resolution.
Although our prospective predication analysis was not adequately powered to demonstrate 
that NfL rate of change is indeed a better predictor of disease progression 
(neurodegeneration and cognitive decline) than absolute NfL values, our observations 
suggest that this is the case in presymptomatic Alzheimer’s disease, while absolute NfL 
levels are better predictors in the symptomatic phase. Absolute NfL levels have been 
successfully used to predict brain volume changes in (symptomatic) multiple sclerosis14 and 
clinical outcome in traumatic brain injury34. In a recent study with Huntington’s disease 
patients, NfL blood levels were predictive of disease onset within three years30, but NfL rate 
of change was not assessed.
The current study design with the 2–3 years interval between participant assessments did not 
allow us to determine the relationship between the time over which the NfL rate of change 
was calculated and its clinical predictability. However, the latter appears important to 
advance the NfL rate of change as a biomarker. Future analyses should also assess more 
accurately the disease period at which the NfL rate of change is a better predictor of 
neurodegeneration and cognitive decline than absolute NfL. Finally, it is important to 
translate our findings to sporadic Alzheimer’s disease and other cerebral proteopathies13,35. 
Studies have indicated that the pathogenesis of familial and sporadic Alzheimer’s disease are 
very similar and share similar pathophysiology and progression36–39. However, sporadic 
Alzheimer’s disease patients are typically older and have more comorbidities, which in turn 
may influence NfL levels in the blood. The latter is however a further argument that absolute 
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NfL levels may be less useful for prediction in early disease stages compared to the NfL rate 
of change.
Methods
Participants.
Participants at 50% risk of carrying an autosomal-dominant Alzheimer’s disease mutation in 
one of three genes (APP, PSEN1, PSEN2) were enrolled in the DIAN observational study 
(National Institute on Aging grant no. U19 AG032438; dian.wustl.edu; clinical trial no. 
NCT00869817)18. DIAN participants are assessed at baseline and subsequent follow-up 
visits (annually to every third year). Assessment included collection of body fluids (CSF, 
blood), clinical testing (CDR), neuropsychological testing (including MMSE (raw scores) 
and the Logical Memory subtest of the Wechsler Memory Scale-Revised (story A), raw 
scores for immediate and delayed recall), and imaging modalities (MRI, PET with 
Pittsburgh Compound B (PiB-PET), and 18F-FDG) as described in earlier 
publications1,2,40–42. The institutional review board at Washington University in St. Louis 
provided supervisory review and human studies approval. Participants or their caregivers 
provided informed consent in accordance with their local institutional review boards. NfL 
analysis in the DIAN cohort was approved by the ethics committee at the medical faculty of 
the University of Tübingen, Germany (project number 718/2014BO2). The detailed number 
of participants (mutation carriers, non-carriers) for baseline and longitudinal measurements 
are given in Supplementary Tables 1 and 2 and the legends of Figs. 2, 3, and 4.
Clinical assessment and EYO.
The presence of dementia (symptoms) was assessed using the CDR41. Clinical evaluators 
were blinded to each participant’s mutation status. For every visit a participant’s EYO was 
calculated based on the participant’s age at the visit relative to their ‘mutation-specific’ 
expected age at dementia onset. The mutation-specific expected age of dementia onset was 
computed by averaging the reported age of dementia onset across individuals with the same 
specific mutation20. If the mutation-specific expected age at dementia onset was unknown, 
the EYO was calculated from the age at which parental cognitive decline began. The 
parental age of clinical symptom onset was determined by a semi-structured interview with 
the use of all available historical data. The EYO was calculated identically for both mutation 
carriers and non-carriers. Mutation status was determined using PCR-based amplification of 
the appropriate exon followed by Sanger sequencing1.
NfL measurements in the CSF and blood.
Fluids were collected in the morning under fasting conditions by venipuncture using a 21 
gauge (G) butterfly needle and red top plain Vacutainer tubes (Becton, Dickinson and 
Company). After blood collection the tubes were left upside at room temperature for 30 min 
to allow clotting. After clotting, tubes were centrifuged at 2,000g for 15 min at room 
temperature. Serum was taken with a disposable, non-sterile transfer pipette into a single 
transfer tube (SARSTEDT AG & Co. KG) and immediately frozen on dry ice. After 
venipuncture, CSF was collected by gravity drip into two 13 ml polypropylene tubes using 
standard lumbar puncture procedures (L4-L5) with an atraumatic Sprotte spinal needle (22 
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G). As with serum, CSF was flash-frozen upright on dry ice. Samples collected in the United 
States were shipped overnight on dry ice to the DIAN biomarker core laboratory at 
Washington University, whereas samples collected at non-United States sites were stored at 
−80 °C and shipped quarterly on dry ice to Washington University. At the core laboratory 
the frozen samples were subsequently thawed, combined into a single polypropylene tube of 
serum or CSF, and aliquoted (300 or 500 μl) into polypropylene Corning microcentrifuge 
tubes (Thermo Fisher Scientific), after which they were again flash-frozen on dry ice and 
stored at −80 °C. For the current study, all available DIAN serum samples (data freeze 11) 
were shipped to the DIAN site in Tübingen. CSF samples (data freeze 9) were shipped to the 
DIAN site in Munich first and used for another analysis before being shipped to the DIAN 
site in Tübingen. Thus, CSF samples had one additional freeze–thaw cycle in Munich; 
however, prior work has indicated no significant effect of up to four freeze–thaw cycles on 
NfL in CSF43.
CSF and serum NfL measurements were performed using a highly sensitive single-molecule 
array assay using the capture monoclonal antibody 47:3 and the biotinylated detection 
antibody 2:1 (UmanDiagnostics AB)44. The samples were measured in duplicate on a Simoa 
HD-1 platform (Quanterix) using a two-step neat assay. Serum samples were measured at 
1:4 and CSF at 1:10 dilution (Tris-buffered saline, 0.1% Tween 20, 1% non-fat milk powder, 
HeteroBlock (300 ug ml−1; Omega Biologicals)). Batch-prepared calibrators (bovine 
lyophilized NfL) ranging from 0 to 10,000 pg ml−1 were stored at −80 °C (Uman 
Diagnostics AB). All samples were measured blinded. For serum, the mean intra-assay 
coefficient of variation of duplicate determinations for concentration was 4.2%. In the CSF, 
the mean intra-assay coefficient of variation was 3.7%. Inter-assay variability was evaluated 
with three native serum samples and three native CSF samples. The inter-assay coefficients 
of variation for serum were 7.7% (mean concentration 13.3 pg ml−1), 2.9% (30.9 pg ml−1), 
and 3.7% (269.9 pg ml−1). In the CSF, the interassay coefficients of variation were 2.4% 
(445.4 pg ml−1), 12.2% (1486.3 pg ml−1), and 13.3% (14,049.0 pg ml−1). Note that the 
concentrations (pg ml−1) are calculated from the full-length NfL calibrator and thus may 
overestimate the concentration of an NfL fragment in the blood.
Imaging.
MRI was performed at the different DIAN sites on 3T scanners using the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) protocol. T1-weighted images (1.1 × 1.1 × 1.2 
mm3 voxels) were acquired for all participants. The ADNI Imaging Core screened images 
for artifacts and protocol compliance. FreeSurfer version 5.3 was used to perform volumetric 
segmentation and cortical surface reconstruction to define subcortical and cortical regions of 
interest (ROIs). Members of the DIAN Imaging Core examined each segmentation and 
edited them as needed. Cortical thickness measures were averaged across hemispheres. 
Since the precuneus region has been shown to be most sensitive to Alzheimer’s disease 
pathophysiology in autosomal-dominant Alzheimer’s disease2,24, we focused our analyses 
on this region a priori.
Amyloid-β-PET imaging was done using a bolus injection of ¹¹C-PiB. Acquisition consisted 
of a 70-min scan starting at injection or a 30-min scan beginning 40 min after injection. Data 
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in the common 40–70 min time frame were converted to regional standardized uptake value 
ratios (SUVRs) relative to the cerebellar gray matter using FreeSurfer-derived ROIs (PET 
Unified Pipeline, https://github.com/ysu001/PUP). Metabolic imaging was done with 18F-
FDG PET with a 30 min dynamic acquisition beginning 30 min after injection. Data from 
the 40–60 min time frame were converted to SUVRs relative to cerebellar gray matter. The 
ADNI Imaging Core verified that the PET images were acquired using the established 
protocol and free of substantial artifacts. All PET data were partial volume-corrected using a 
regional spread function technique. Scanner-specific spatial filters were applied to achieve a 
common resolution (8 mm) across PET scanners. MRI and PET data acquisition and 
processing has been described in detail in previous studies1,2,24. Again, for the present 
analyses, we averaged SUVR values from the bilateral precuneus ROIs defined on the MRI.
Statistical analysis.
Relating baseline CSF and serum NfL.—The relationship between baseline CSF and 
serum NfL was determined by using LMEMs implemented in R version 3.4.2 and RStudio 
version 1.1.453 using the package lme4, including a random intercept term for family and 
fixed effect for baseline age, sex, and baseline CSF NfL, with baseline serum NfL as the 
dependent variable. Separate models were fitted for non-carriers and mutation carriers. 
Baseline CSF and serum NfL values were log-transformed (due to non-normal distribution) 
before being entered into the model. See also Supplementary statistical analysis.
Baseline CSF and serum NfL as a function of EYO.—The relationship between 
EYO and baseline CSF and serum NfL values was estimated using LMEMs. As previously 
done, to account for potential non-linear effects, EYO was modeled as a restricted cubic 
spline with knots at the 0.10, 0.50, and 0.90 quantiles2. The LMEMs for the baseline NfL 
values (CSF or serum) included: fixed effects for mutation status; the linear EYO 
component; the cubic EYO component; the linear EYO by mutation status interaction; the 
cubic EYO by mutation status interaction; and a random intercept for family. Model 
parameters were estimated using an open source package for Hamiltonian Markov chain 
Monte Carlo analyses, Stan (http://mc-stan.org/)45,46, implemented using R. This resampling 
approach leads to a distribution of parameter estimates across iterations. From this 
distribution it is possible to estimate the 99% credible intervals of the model fits at every 
EYO for non-carriers, mutation carriers, and the distribution of the difference between non-
carriers and mutation carriers. The first EYO where groups (non-carriers and mutation 
carriers) differed was determined to be the first point where the 99% credible intervals 
around the differences distribution between non-carriers and mutation carriers did not 
overlap 0. See also Supplementary statistical analysis.
Calculating the rate of change in biomarkers.—Longitudinal data was modeled 
using LMEMs. LMEMs are a powerful approach to account for the covariance structure 
introduced by serial measurements and are ideal to deal with imperfect timing or an 
unbalanced number of data points. The rate of change in log-transformed serum NfL for 
each individual was modeled using an LMEM with fixed effects of time from baseline (in 
years), mutation status, a time from baseline by mutation status interaction, and a random 
intercept for family, as well as random slope and intercept terms for each participant. The 
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rate of NfL change for each individual was extracted from the model estimates for 
subsequent analyses. This model was also used for generating the rate of change for cortical 
thickness,18F-FDG PET, and PiB-PET, for each individual (for plotting purposes). See also 
Supplementary statistical analysis.
Longitudinal serum NfL as a function of EYO and cognitive status.—As with the 
cross-sectional estimates, the relationship between EYO and rate of change in serum NfL 
was estimated using an LMEM in Stan. The EYO was modeled as a restricted cubic spline 
with knots at the 0.10, 0.50, and 0.90 quantiles. The LMEM model for the rate of change in 
serum NfL included: fixed effects for mutation status; the linear EYO component; the cubic 
EYO component; the linear EYO by mutation status interaction; the cubic EYO by mutation 
status interaction; and a random intercept for family. Model parameters were estimated using 
Stan. Again, this resampling approach leads to a distribution of parameters estimates across 
iterations, resulting in 99% credible intervals of the model fits at every EYO for non-
carriers, mutation carriers, and the distribution of the difference between non-carriers and 
mutation carriers. The first EYO where groups (non-carriers and mutation carriers) differed 
was determined to be the first point where the 99% credible intervals around the differences 
distribution between non-carriers and mutation carriers did not overlap 0.
To determine whether the extracted rate of change in serum NfL was significantly different 
across mutation status and cognitive status we categorized mutation carriers based on 
cognitive status, where presymptomatic mutation carriers were individuals who scored as 
CDR = 0 across all visits (n = 65), converters were mutation carriers who scored as CDR = 0 
at baseline and CDR > 0 at subsequent visits (n = 13), and symptomatic mutation carriers 
were individuals who scored as CDR > 0 across all visits (n = 55). We used LMEMs, 
including a random intercept for family and fixed effects for baseline age, sex, and group 
(that is, non-carriers, presymptomatic mutation carriers, converters, or symptomatic 
mutation carriers), where group was the term of interest, and the extracted rate of change in 
serum NfL was the dependent variable. Models were computed using lme4 in R. See also 
Supplementary statistical analysis.
Association between expected age of onset and deviation from the EYO-
adjusted median rate of change in NfL.—We tested the hypothesis of whether 
individuals who have an earlier expected age of onset (for example, age of onset of 30 years 
old versus 55 years old) have an accelerated NfL rate of change. First, to determine if a 
participant deviated from its expected NfL rate of change, given its baseline EYO, we 
calculated the median rate of change in NfL at each EYO, generated from model estimates 
(for the calculation, see ‘Baseline CSF and serum NfL and longitudinal NfL as a function of 
EYO’ in the Supplementary statistical analysis; for the depiction of median values, see the 
red line in Fig. 2b). We then took each participant’s extracted NfL rate of change and 
subtracted the median value corresponding to its baseline EYO. This resulting value 
represented the deviation from the expected value, whereby a positive value on this deviation 
measure indicates that an individual has a higher rate of change in serum NfL (that is, 
worse) than would be expected given their EYO. Conversely, a negative value on this 
deviation measure indicates that an individual has a lower rate of change in serum NfL (that 
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is, better) than would be expected given their EYO. Next, to investigate if there was a 
relationship between individuals with the higher deviation measure and earlier expected age 
of onset, we grouped individuals by their expected age of onset (determined by their specific 
mutation type, grouped as age of onset 20–39, 40–49, 50–59, and 60+). See also 
Supplementary statistical analysis.
Relating NfL rate of change to imaging rate of change.—The longitudinal 
relationship between the rate of change in serum NfL and concurrent rate of change in 
cortical thickness, metabolism, or amyloid-β accumulation was determined within each 
group of interest (that is, non-carriers, presymptomatic mutation carriers, and symptomatic 
mutation carriers). Therefore, separate models were run for each non-carrier, 
presymptomatic mutation carrier, and symptomatic mutation carrier groups. The dependent 
term for each model was an imaging biomarker with fixed effect terms for baseline age, sex, 
time from baseline, extracted rate of change in serum NfL, and interaction between time 
from baseline and rate of change in serum NfL. Models contained random slope and 
intercept terms for participants and random intercepts for family. The primary term of 
interest was the interaction between the rate of change in serum NfL and the time from 
baseline term. Models were fitted using lme4 in R.
To determine whether the relationship between groups was different, a model for each 
imaging modality containing all groups was run. Each model was fitted containing fixed 
effect terms for baseline age, sex, time from baseline, extracted rate of change in serum NfL, 
group (non-carriers, presymptomatic mutation carriers, or symptomatic mutation carriers), 
and two- and three-way interaction between time from baseline, rate of change in serum 
NfL, and group. Converters were included as part of the symptomatic mutation carrier 
group. The models also included random slope and intercept terms for the participants and 
random intercepts for family. The dependent variables were the longitudinal measures for 
cortical thickness, glucose metabolism, or amyloid-β deposition in the precuneus ROI. See 
also Supplementary statistical analysis.
Serum NfL at baseline predicts annual changes in cortical thickness and 
cognition.—To examine whether baseline serum NfL could predict subsequent changes in 
cortical thickness and cognition in mutation carriers we fitted LMEMs with random slope 
and intercept terms for participants, random intercepts for family, and fixed effect terms for 
baseline age, sex, time, log-transformed baseline serum NfL, and an interaction between 
time and baseline serum NfL. The interaction term was the term of interest. The dependent 
terms entered into the models were longitudinal precuneus cortical thickness measurements, 
MMSE scores, and Logical Memory test scores. If significant, an association of baseline 
serum NfL with rate of change in cortical thickness or cognition was assumed. See also 
Supplementary statistical analysis.
Prospective prediction of cortical thickness and cognition by serum NfL rate 
of change.—To determine whether the rate of change in serum NfL could predict 
subsequent changes in cortical thickness or cognition, we conducted a truly prospective 
study, whereby after longitudinal serum collection for NfL, we collected additional imaging 
and neuropsychological data on 39 mutation carriers. Twenty-eight individuals completed 
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additional imaging and neuropsychological testing, 9 completed only additional 
neuropsychological testing but no MRI, and 2 who completed an additional MRI but not 
neuropsychological testing. To determine the rate of change in cortical thickness and 
cognition (MMSE, Logical Memory test) between the imaging and cognitive assessment 
concurrent to the participant’s last blood draw and follow-up session, we fitted an LMEM 
for each participant, where the dependent variable was the imaging or cognitive variable of 
interest at last serum visit and follow-up visit and the independent variable was the time 
between visits. Models were run in R. We then used this rate of change for cortical thickness 
or cognition as the dependent variable in an LMEM, which included fixed effects for age, 
sex, and the rate of change in serum NfL, and a random intercept term for family. The term 
of interest was the serum NfL rate of change. Models were fitted using lme4 in R. See also 
Supplementary statistical analysis.
Further statistical analyses and models.—The unstandardized regression coefficients 
(B), standard error of the mean (s.e.m.), and P values from the LMEMs and linear regression 
models are reported in the figure legends. The statistical analyses mentioned in the figure 
legends of Extended Data Figs. 2–4 and Supplementary Tables 1 and 2 were conducted 
using the JMP software, version 13.0 (SAS Institute Inc.). For the analysis of Extended Data 
Fig. 3c a regression model was created, which approximates the changes of non-carriers and 
mutation carriers. The model uses the rate of change of log serum NfL over EYO. For non-
carriers a slightly increasing line over the entire time period was created representing the 
NfL increase over age. For mutation carriers the same development was taken for the very 
early years until a bifurcation point indicating the divergence of non-carriers and mutation 
carriers. From this point on, mutation carriers were shown with a rising slope up to a break 
of slope, when the line came to a parallel increase as non-carriers. This model uses one 
common slope at the very beginning, one bifurcation point, and one shift leading to two 
parallel slopes after symptom onset. See also Supplementary statistical analysis.
Reporting Summary.
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Extended Data
Extended Data Fig. 1 |. Difference distribution curve for baseline (cross-sectional) CSF and 
serum NfL levels in mutation carriers and non-carriers.
a,b, Difference of posterior distribution for baseline CSF NfL (n = 187) (a) and baseline 
serum NfL (n = 405) (b) as a function of EYO. The solid red lines depict the median of the 
difference distribution; the shaded area represents the 99% equal-tailed credible intervals. 
EYO was considered statistically significant if the 99% equal-tailed credible intervals of the 
posterior distribution did not overlap 0 (6.8 years before EYO for both baseline CSF and 
serum NfL). For the absolute values of baseline CSF and serum NfL, see Fig. 1a,b.
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Extended Data Fig. 2 |. No difference in baseline CSF and serum NfL levels among APP, PSEN1, 
and PSEN2 mutation carriers.
a, Two-tailed pairwise Student’s t-test comparisons of CSF NfL levels of carriers of a 
mutation in APP (n = 14), PSEN1 (n = 82), or PSEN2 (n = 11). b, Same analysis, using a 
two-tailed pairwise Student’s t-test for the serum NfL of carriers of a mutation in APP (n = 
39), PSEN1 (n = 185), or PSEN2 (n = 19). No differences in log(CSF NfL) or log(serum 
NfL) were found between the groups (F(2, 104)= 1.8108, P = 0.1686 and F(2, 240)= 1.9205, 
P = 0.1488, respectively). Similarly, no differences were found by two-tailed pairwise 
Student’s t-test when age and disease status (presymptomatic, symptomatic) were treated as 
covariates. The boxes map to the median, 25th and 75th quintiles, and the whiskers extend to 
the 1.5 × IQR.
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Extended Data Fig. 3 |. Longitudinal serum NfL and bifurcation of mutation carriers from non-
carriers.
a, Spaghetti plot showing longitudinal serum NfL for non-carriers (NC, n = 63, blue) and 
mutation carriers (MC, n = 133, red) as a function of EYO. These are the same data as in 
Fig. 2a but with a logarithmic scale on the y axis to better appreciate the changes during the 
presymptomatic stage (for details, see Fig. 2a). b, Difference of posterior distribution for 
serum NfL rate of change between mutation carriers and non-carriers, as a function of EYO 
(n = 196). The solid red line depicts the median of the difference distribution, and the shaded 
area represents the 99% equal-tailed credible intervals. EYO was considered statistically 
significant if the 99% equal-tailed credible intervals of the posterior distribution did not 
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overlap 0 (16.2 years before EYO). c, Individual estimated rate of change in serum NfL 
(same data as in Fig. 2b, n = 63 for non-carriers and n = 133 for mutation carriers). A 
regression analysis was performed with two breaks of slope (see Methods for calculation). 
With this model the first bifurcation point was found at −18.6 years before EYO, the second 
at −5.8 years before EYO.
Extended Data Fig. 4 |. Rate of change per year of serum NfL is a better parameter to distinguish 
presymptomatic and symptomatic mutation carriers from non-carriers compared to single cross-
sectional serum NfL.
Receiver operating characteristic analysis for non-carriers (NC) versus presymptomatic 
mutation carriers (MC) and non-carriers versus symptomatic mutation carriers with cross-
sectional (baseline serum NfL) and longitudinal (serum NfL rate of change per year) data. 
The true positive fraction (sensitivity) is on the y axis and the false positive fraction (1-
specificity) on the x axis. The area under the curve (AUC, accuracy), as well as the cutoff 
value and χ2 P value from the logistic regression are shown. The chance level of the area 
under the curve is 0.50. Converters (for rate of change, see Fig. 2c) were considered 
presymptomatic mutation carriers.
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Extended Data Fig. 5 |. No difference in serum NfL rate of change among APP, PSEN1, and 
PSEN2 mutation carriers and no association with estimated age of onset.
a, Using two-tailed pairwise Student’s t-tests, no differences in the rate of change of 
log(serum NfL) (year−1) levels among APP (n = 24), PSEN1 (n = 104), and PSEN2 (n = 5) 
mutation carriers (F(2, 130) = 0.4678, P = 0.6274) was found. Similarly, no differences were 
found when age and disease status (presymptomatic, symptomatic) were treated as 
covariates in a two-tailed pairwise Student’s t-test. b, No difference between an individual’s 
deviation from the EYO-adjusted median rate of change in NfL and their expected age of 
symptom onset using LMEMs. Individuals were grouped in 4 categories with expected 
symptom onset at 20–39 (n = 17), 40–49 (n = 54), 50–59 (n = 56), and over 60 years of age 
(n = 6); group comparisons, P > 0.146. See Methods for the calculations. The boxes map to 
the median, 25th and 75th quintiles, and the whiskers extend to the 1.5 × IQR.
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Fig. 1 |. CSF and serum NfL levels are highly correlated and divert between mutation carriers 
and non-carriers already in the presymptomatic phase.
a, CSF NfL values of non-carriers (blue, n = 80) and mutation carriers (red, n = 107) as a 
function of EYO. Shown is −27.5 until +15 years before or after EYO, respectively. b, 
Serum NfL for non-carriers (n = 162) and mutation carriers (n = 243) as a function of EYO. 
For a and b, the shaded areas represent the 99% credible intervals around the model 
estimates. The curves and credible intervals are drawn from the actual distributions of model 
fits derived by the Hamiltonian Markov chain Monte Carlo analyses (see Methods). The first 
EYO where non-carriers and mutation carriers differed was determined to be the first point 
where the 99% credible intervals around the difference distribution between non-carriers and 
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mutation carriers did not overlap 0 (−6.8 years before EYO for both CSF and serum, see 
Extended Data Fig. 1). Our analysis is influenced by the available number of participants. 
Thus, results do not represent absolute measures, but rather relative EYO points where we 
could detect effects given the limitations of sample size. c,d, Significant associations from 
LMEMs between CSF NfL and serum NfL in non-carriers (n = 80; B(s.e.m.) = 0.350(0.14), 
P = 0.014) and mutation carriers (n = 107; B(s.e.m.) = 0.612(0.05), P < 2.0 × 10−16) were 
found.
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Fig. 2 |. Longitudinal serum NfL distinguishes mutation carriers from non-carriers very early in 
the presymptomatic disease process, with the NfL rate of change peaking in individuals 
converting from the presymptomatic to the symptomatic phase.
a, Spaghetti plot showing longitudinal serum NfL for non-carriers (blue, n = 63) and 
mutation carriers (red, n = 133) as a function of EYO. The displayed x axis range is limited 
to −27.5 until +12.5 years before or after EYO, respectively, to maintain blinding of some 
individuals contributing to this dataset. In addition, again to maintain blinding, the EYO of 
two participants (one mutation carrier and one non-carrier) was set to the mean of both EYO 
values. A logarithmic version of the spaghetti plot is shown in Extended Data Fig. 3a to 
better appreciate that changes between mutation carriers and non-carriers already occur at 
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presymptomatic levels. b, Estimated rate of change per year in serum NfL (see Methods for 
calculation) plotted against baseline EYO for mutation carriers and non-carriers (shown is 
−27.5 until +12.5 years). Individual random effect slope estimates are plotted as colored 
symbols. The shaded areas represent the 99% credible intervals around the model estimates. 
The curves and credible intervals are drawn from the actual distributions of model fits 
derived with the Hamiltonian Markov chain Monte Carlo analyses. The first EYO where 
groups (non-carriers and mutation carriers) differed was determined to be the first point 
where the 99% credible intervals around the difference distribution between non-carriers and 
mutation carriers did not overlap 0 (−16.2 years before EYO; see Extended Data Fig. 3b). 
An even earlier deviation of the two curves was calculated when linear regression analyses 
were performed (Extended Data Fig. 3c). c, Rate of change per year in serum NfL across 
four groups differing by mutation and cognitive status: non-carriers (blue, n = 63); 
presymptomatic (Presym) mutation carriers (yellow, n = 65) are individuals who scored as 
CDR= 0 across all visits; converters (orange, n = 13) are mutation carriers who scored as 
CDR= 0 at baseline and CDR> 0 at subsequent visits; symptomatic (Sym) mutation carriers 
(red, n = 55) are individuals who scored as CDR> 0 across all visits. The boxes map to the 
median, 25th and 75th quintiles, and the whiskers extend to 1.5 × interquartile range (IQR). 
Comparisons were done with LMEMs. Presymptomatic mutation carriers had a significantly 
higher annual rate of change compared to non-carriers (B(s.e.m.) = 0.009(0.003), P = 6.71 × 
10−4). Converters had significantly higher rate of change compared to both non-carriers 
(B(s.e.m.) = 0.024(0.004), P = 3.05 × 10−7) and presymptomatic mutation carriers (B(s.e.m.) 
= 0.015(0.005), P = 1.19 × 10−3). Symptomatic mutation carriers had significantly higher 
rates of change compared to both non-carriers (B(s.e.m.) = 0.020(0.003), P = 8.78 × 10−12) 
and presymptomatic mutation carriers (B(s.e.m.) = 0.011(0.003), P = 1.51 × 10−4). There 
was no difference between converters and symptomatic mutation carriers (B(s.e.m.) = 
−0.004(0.005), P = 0.445).
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Fig. 3 |. Rate of change per year in serum NfL in mutation carriers mirrors rate of change in 
cortical thinning.
a, Relationship between estimated annual rate of change in serum NfL and estimated annual 
rate of change in precuneus cortical thickness for non-carriers, presymptomatic (Presym) 
mutation carriers, and symptomatic (Sym) mutation carriers (including converters to the 
symptomatic phase, see Fig. 2c). Results from LMEMs revealed a significant association in 
symptomatic mutation carriers (n = 60; B(s.e.m.) = −0.914(0.367), P = 0.018) and a close to 
significant association in presymptomatic mutation carriers (n = 65; B(s.e.m.) = 
−0.325(0.166), P = 0.054) but not in non-carriers (n = 59; B(s.e.m.) = −0.210(0.149), P = 
0.886). Between-group comparison indicated that the rate of change in serum NfL was 
slightly more associated in symptomatic than in asymptomatic mutation carriers (B(s.e.m.) = 
−0.573(0.305), P = 0.063). b, Relationship between rate of change in serum NfL and rate of 
change in precuneus 18F-FDG PET. Using LMEMs, a positive association was only found 
in symptomatic mutation carriers (n = 55; B(s.e.m.) = −1.149(0.501), P = 0.031) but not in 
presymptomatic mutation carriers (n = 64; B(s.e.m.) = −0.227(0.456), P = 0.620) or non-
carriers (n = 55; B(s.e.m.) = 0.161(0.347), P = 0.465). c, Relationship between rate of 
change in serum NfL and rate of change in precuneus amyloid-β-PET. Using LMEMs, no 
significant association in any of the three groups was found (non-carriers: n = 57; B(s.e.m.) 
= −0.468(0.547), P = 0.403; presymptomatic mutation carriers: n = 64; B(s.e.m.) = 
1.248(1.000), P = 0.216; symptomatic mutation carriers: n = 51; B(s.e.m.) = 1.805(1.556), P 
= 0.266). The shaded area around each linear fit line represents one s.e.m. Note that not all 
participants with longitudinal NfL measurements had imaging parameters available, thus 
sample sizes (n) are slightly lower compared to those in Fig. 2c.
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Fig. 4 |. Prediction of changes in cortical thinning and cognition by baseline serum NfL 
(retrospective prediction) and serum NfL rate of change (prospective prediction).
a–c, Higher baseline serum NfL levels were significantly associated with an increased rate 
of change in cortical thickness (n = 125; B(s.e.m.) = −0.105(0.013), P = 4.47 × 10−13) (a), 
MMSE (n = 132; B(s.e.m.) = −3.980(0.537), P = 2.38 × 10−11) (b), and Logical Memory test 
(immediate recall, n = 133; B(s.e.m.) = −1.478(0.502), P = 0.004) (c). A similar significance 
(P = 0.015) was obtained for the Logical Memory test delayed recall. LMEMs (see 
Methods) were run with all mutation carriers together (n = 125) because of the high degree 
of overlap in cognitive and biomarker levels between presymptomatic (Presym) and 
symptomatic (Sym) mutation carriers. However, at least for cortical thickness, separate 
analyses for presymptomatic and symptomatic mutation carriers were also significant (n = 
65, presymptomatic mutation carriers (yellow): B(s.e.m.) = −0.03(0.01), P = 0.047; n = 60, 
symptomatic mutation carriers (red): B(s.e.m.) = −0.10(0.03), P = 0.002). d–f, In a true 
prospective design, mutation carriers returning for follow-up visits after the last serum 
collection were included in the analysis. Individuals’ rates of change in serum NfL levels 
predicted subsequent cortical thinning (d; n = 30; B(s.e.m.) = −1.867(0.769), P = 0.024). 
The same predictive associations were also significant for the MMSE (e; n = 37; B(s.e.m.) = 
−52.23(20.19), P = 0.015) and Logical Memory test scores (f; immediate recall, n = 37; 
B(s.e.m.) = −75.91(18.07), P = 0.0002). For descriptive purposes, presymptomatic and 
symptomatic mutation carriers are plotted in yellow and red, respectively. Note that not all 
participants with baseline NfL measurements had longitudinal MRI imaging and 
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longitudinal cognitive parameters available; thus, sample sizes (n) in a–c are slightly lower 
than those in Supplementary Table 2. This was also true for the mutation carriers returning 
for follow-up visits after the last serum collection (d–f). The shaded area around each linear 
fit line represents one s.e.m. from the LMEMs.
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